Acute coronary syndromes: summary of updated NICE guidance
- PMID: 33452009
- DOI: 10.1136/bmj.m4760
Acute coronary syndromes: summary of updated NICE guidance
Conflict of interest statement
Competing interests: We declared the following interests based on NICE’s policy on conflicts of interests (https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf): SF, SL, and KL are employees of the National Guideline Centre, which is commissioned and funded by NICE to develop clinical guidelines. SC and the guideline authors’ full statements can be viewed at https://www.nice.org.uk/guidance/ng185/documents/register-of-interests-2
Similar articles
-
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006275. doi: 10.1161/CIRCOUTCOMES.119.006275. Epub 2020 Mar 11. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32156164
-
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.Atherosclerosis. 2019 Feb;281:98-106. doi: 10.1016/j.atherosclerosis.2018.11.037. Epub 2018 Dec 7. Atherosclerosis. 2019. PMID: 30658197
-
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6. BMC Cardiovasc Disord. 2020. PMID: 32164560 Free PMC article.
-
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764. G Ital Cardiol (Rome). 2020. PMID: 32100728 Italian. No abstract available.
-
Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.Curr Pharm Des. 2018;24(4):465-477. doi: 10.2174/1381612824666180108121834. Curr Pharm Des. 2018. PMID: 29308737 Review.
Cited by
-
Use of machine learning models to predict in-hospital mortality in patients with acute coronary syndrome.Clin Cardiol. 2023 Feb;46(2):184-194. doi: 10.1002/clc.23957. Epub 2022 Dec 7. Clin Cardiol. 2023. PMID: 36479714 Free PMC article.
-
Reply to Kielb et al. Untapped Potential for Female Patients? Comment on "Lucà et al. Update on Management of Cardiovascular Diseases in Women. J. Clin. Med. 2022, 11, 1176".J Clin Med. 2022 May 30;11(11):3086. doi: 10.3390/jcm11113086. J Clin Med. 2022. PMID: 35683475 Free PMC article.
-
The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Expert Rev Clin Pharmacol. 2022 Jul;15(7):811-825. doi: 10.1080/17512433.2022.2108401. Epub 2022 Aug 4. Expert Rev Clin Pharmacol. 2022. PMID: 35912831 Free PMC article.
-
In-Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC-ACS Project.J Am Heart Assoc. 2024 Oct;13(19):e029252. doi: 10.1161/JAHA.122.029252. Epub 2024 Sep 18. J Am Heart Assoc. 2024. PMID: 39291502 Free PMC article.
-
Effects of Cardiac Telerehabilitation During COVID-19 on Cardiorespiratory Capacities in Patients With Coronary Artery Disease.Front Physiol. 2022 Mar 17;13:837482. doi: 10.3389/fphys.2022.837482. eCollection 2022. Front Physiol. 2022. PMID: 35370786 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical